2024-12-10 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Review

This report analyzes Eli Lilly and Co. (LLY), a leading pharmaceutical company, based on the provided data.

**1. Performance vs. S&P 500 (VOO):**

Eli Lilly's cumulative return (587.198%) significantly outperforms the S&P 500's (120.726%).  The difference is 466.5%, placing it at the 74.5th percentile of the historical range of the difference between LLY and VOO's returns.  This indicates a substantial outperformance relative to the market.  The provided CAGR data further supports this, showing consistently high growth rates over various periods.

**2. Recent Price Movement:**

* **Closing Price:** $803.58
* **5-day Moving Average:** $819.82
* **20-day Moving Average:** $786.26
* **60-day Moving Average:** $853.50

The price is below all three moving averages, suggesting a potential short-term downward trend, although the difference is not substantial. The last market price of 803.21 is very close to the closing price, indicating minimal change since market close.

**3. Technical Indicators and Expected Return:**

* **RSI:** 76.49 – This suggests the stock is in overbought territory, indicating potential for a short-term correction.
* **PPO:** 1.22 – A positive PPO suggests bullish momentum.
* **20-day Relative Divergence:** +0.5 – Indicates a recent short-term upward trend.
* **Expected Return:** 538.4% – This exceptionally high projected return, relative to the S&P 500, needs further context.  It's crucial to understand the assumptions behind this projection.

Given the 803.21 closing price and the moving averages, there is no evidence of a sudden spike or drop.  The high RSI suggests caution regarding potential near-term price corrections.

**4. Recent Earnings Analysis:**

The provided earnings data shows volatility:

* **Revenue:** Shows a general upward trend, though with some fluctuation.  There's a significant drop in Q1 2024, followed by an increase in subsequent quarters.
* **EPS:** High variability is present, with a significant negative EPS in two instances. This erratic behavior requires deeper analysis to ascertain the root cause. This inconsistency needs further investigation beyond the provided data.

**5. Financial Information:**

* **Revenue and Profitability:** Revenue shows some volatility, but generally maintains a relatively high level.  Profit margins remain consistently high (above 80%), indicating strong profitability.
* **Capital and Profitability:**  Equity shows a generally increasing trend, while ROE is highly variable.  The significant negative ROE in Q3 2023 needs further exploration.

The inconsistency in ROE suggests potential volatility in profitability. More in-depth analysis is needed to understand the underlying drivers.


**6. News and Recent Issues:**

No specific news or analyst opinions are provided in the data. This section requires additional information.


**7. Overall Analysis:**

Eli Lilly shows strong long-term growth, significantly outperforming the S&P 500. However, recent data reveals some concerns. The high RSI suggests potential short-term corrections.  The erratic EPS and ROE figures necessitate a thorough investigation into underlying factors.  The exceptionally high projected return requires further examination and context.  More information is needed on recent news and analyst opinions to form a complete picture.  The provided data paints a picture of a company with significant long-term potential, but with short-term volatility and some irregularities needing further analysis.


**8.  Disclaimer:** This analysis is based solely on the provided data.  A comprehensive investment decision should consider additional factors, including broader market conditions, detailed financial statements, and thorough risk assessment.  This is not financial advice.
